A Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination With Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia

Micro-Abstract A phase I study of targeted, dose-escalated busulfan in combination with etoposide as myeloablative therapy for autologous hematopoietic stem cell transplantation in acute myeloid leukemia identified a busulfan area under the curve (AUC) target of 1400 μmol/min as the maximum clinical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2015-06, Vol.15 (6), p.377-383
Hauptverfasser: Mannis, Gabriel N, Andreadis, Charalambos, Logan, Aaron C, Damon, Lloyd E, Benet, Leslie Z, Ai, Weiyun Z, Gaensler, Karin M.L, Kaplan, Lawrence D, Koplowicz, Yelena B, Linker, Charles A, Olin, Rebecca L, Sayre, Peter H, Smith, Catherine C, Sudhindra, Akshay, Venstrom, Jeffrey M, Wolf, Jeffrey L, Martin, Thomas G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Micro-Abstract A phase I study of targeted, dose-escalated busulfan in combination with etoposide as myeloablative therapy for autologous hematopoietic stem cell transplantation in acute myeloid leukemia identified a busulfan area under the curve (AUC) target of 1400 μmol/min as the maximum clinically acceptable dose. This busulfan AUC target might be associated with improved relapse-free survival.
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2015.02.016